Clinical Trial

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-08-26; most recent amendment 2025-09-05.
Status change: Recruiting → Active, Not Recruiting 2021-12-10
Status change: Not Yet Recruiting → Recruiting 2020-10-02
Trial Details
NCT Number NCT04533581
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions Indolent B-cell Non-Hodgkin's Lymphoma
Enrollment 61 participants
Start Date 2020-09-17
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-11